Evidence boundary
Current NAD+ studies do not provide a subcutaneous redness rate
Human evidence for direct NAD+ administration remains limited. A small 2026 retrospective pilot studied four days of supervised IV NAD+ or IV nicotinamide riboside in a commercial setting, while a 2026 critical review described evidence for IV longevity therapies as sparse and heterogeneous. Neither source studied patient-specific compounded subcutaneous NAD+ injection-site redness or established its incidence, size, onset, duration, cause, prevention, or treatment. IV infusion findings also cannot be transferred into an at-home subcutaneous reaction rule.
- Do not invent a redness percentage or promise that a local mark should disappear within a fixed number of hours or days.
- Timing after treatment is important to document, but timing alone cannot distinguish irritation, hematoma, allergy, infection, tissue injury, or a product-quality concern.
- Redness is not proof of detoxification, cellular repair, absorption, potency, treatment benefit, or a correct injection.
Describe the site
Redness alone does not show whether a reaction is minor or urgent
A small stable area of redness can look very different from expanding redness with increasing warmth or pain. Itching, tenderness, bruising, a firm area, swelling, drainage, streaking, blistering, darkening, fever, and symptoms away from the site change the assessment. MedlinePlus notes that cellulitis can involve redness, warmth, tenderness, pain, swelling, fever, or red streaks, while anaphylaxis can involve hives, facial or throat swelling, wheezing, breathing difficulty, dizziness, or fainting. A photo or symptom list cannot diagnose either condition.
- Document when the change began, whether its border is stable or spreading, the pain and warmth trend, firmness, drainage, fever, and symptoms elsewhere.
- Tell the clinician about diabetes, immune suppression, circulation or skin disease, prior local or allergic reactions, easy bruising, and anticoagulant or antiplatelet medicines.
- Persistent, recurrent, enlarging, unusually painful, draining, or treatment-limiting redness deserves clinical review even when a seller calls it expected.
Product and route identity
Compounded NAD+ injections are not FDA-approved finished drug products
Peptide12 lists a clinician-reviewed patient-specific compounded NAD+ subcutaneous injection pathway. That product is not an FDA-approved finished drug for fatigue, cognition, anti-aging, longevity, or any injection-site condition. FDA explains that compounded drugs are not reviewed before marketing for safety, effectiveness, and quality in the same way as approved products. Concentration, excipients, container, supplies, storage, beyond-use date, and dispensing pharmacy can matter when a local reaction follows a first use or new refill.
- Confirm the active ingredient, route, concentration, other ingredients, dispensing pharmacy, patient label, lot or refill information, beyond-use date, storage instructions, prescriber, and adverse-event contact.
- Report a changed refill, different concentration or ingredient, delayed shipment, temperature concern, damaged packaging, cloudiness, particles, discoloration, or missing label before further use.
- Avoid research-use vials, no-prescription checkout, hidden pharmacy sourcing, unlabeled blends, copied injection maps, reconstitution instructions, and claims that redness proves potency.
What not to improvise
Do not redose or self-treat a concerning site from a forum protocol
The next treatment decision depends on symptom severity and spread, infection or allergy features, bleeding risk, product identity, and an examination when needed. Repeating or changing treatment, squeezing or draining a lump, vigorously rubbing the area, applying prescription creams, using leftover antibiotics, or adding an antihistamine or pain medicine can delay diagnosis or add interaction, allergy, sedation, bleeding, kidney, liver, or symptom-masking risks. The responsible prescriber should decide whether treatment pauses and whether the site, product, pharmacy, or adverse event needs further assessment.
- Do not repeat, increase, split, retime, switch routes, or change products to test whether the reaction happens again.
- Do not stop a prescribed anticoagulant, antiplatelet medicine, diabetes medicine, or immune treatment on your own because of local redness or bruising.
- Preserve photos and product details, but do not let portal messaging delay in-person care when symptoms are rapidly worsening or severe.
Escalation
Separate prescriber follow-up from infection and allergy emergencies
Mild stable redness may be appropriate for prescriber follow-up, but rapidly spreading redness or swelling, severe or escalating pain, pus, red streaks, fever, blistering, darkening, skin breakdown, or feeling acutely unwell can require prompt local assessment. Widespread hives, wheezing, breathing difficulty, throat tightness, facial or tongue swelling, fainting, confusion, or rapidly developing whole-body symptoms are not routine local reactions and can require emergency care.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or rapidly developing widespread hives or swelling.
- Seek prompt local assessment for rapid spread, severe or disproportionate pain, pus or drainage, red streaks, fever or chills, blistering, darkening, or skin breakdown.
- Contact the prescriber for persistent, recurrent, enlarging, unusually painful, or treatment-limiting redness and before another treatment or route decision.